Washington Trust’s Voyager Therapeutics VYGR Stock Holding History

Washington Trust’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$2.92K	–	888
2024 Q3	$2.92K	Hold	500	–	–	﹤0.01%	781
2024 Q2	$3.96K	Hold	500	–	–	﹤0.01%	765
2024 Q1	$4.66K	Hold	500	–	–	﹤0.01%	748
2023 Q4	$4.22K	Hold	500	–	–	﹤0.01%	731
2023 Q3	$3.88K	Hold	500	–	–	﹤0.01%	713
2023 Q2	$5.72K	Hold	500	–	–	﹤0.01%	695
2023 Q1	$3.85K	Hold	500	–	–	﹤0.01%	747
2022 Q4	$3.05K	Hold	500	–	–	﹤0.01%	766
2022 Q3	$3K	Hold	500	–	–	﹤0.01%	779
2022 Q2	$3K	Hold	500	–	–	﹤0.01%	784
2022 Q1	$4K	Hold	500	–	–	﹤0.01%	770
2021 Q4	$1K	Hold	500	–	–	﹤0.01%	922
2021 Q3	$1K	Hold	500	–	–	﹤0.01%	1044
2021 Q2	$2K	Hold	500	–	–	﹤0.01%	968
2021 Q1	$2K	Hold	500	–	–	﹤0.01%	927
2020 Q4	$4K	Hold	500	–	–	﹤0.01%	822
2020 Q3	$5K	Hold	500	–	–	﹤0.01%	808
2020 Q2	$6K	Hold	500	–	–	﹤0.01%	697
2020 Q1	$5K	Buy	+500	New	+$5.74K	﹤0.01%	764
2018 Q3	–	Sell	-500	Closed	-$10K	–	806
2018 Q2	$10K	Buy	+500	New	+$9.88K	﹤0.01%	680

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Washington Trust's VYGR Position: Q4 2024 in Review

Washington Trust sold out of Voyager Therapeutics (VYGR) in Q4 2024, closing a stake of 500 shares — an estimated $2.92K sold.

Washington Trust first reported a position in VYGR in Q2 2018 and held it in 20 quarters. The position peaked at $10K in Q2 2018. 132 funds tracked by Wall St. Rank hold VYGR as of Q4 2024.

Washington Trust reported no remaining Voyager Therapeutics position as of Q4 2024 after selling out during the quarter.
Washington Trust sold 500 Voyager Therapeutics shares in Q4 2024, an estimated $2.92K.
Washington Trust first reported a position in Voyager Therapeutics in Q2 2018 and held it in 20 quarters.
Washington Trust's Voyager Therapeutics position peaked at $10K in Q2 2018.
132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2024.

Based on Washington Trust's 13F filing for Q4 2024, filed 30 Jan 2025.